Technology in Cancer Research & Treatment · 2020 · 14 citations · 17 references
MedicineHematologyOncologyGene ExpressionGene Expression AnalysisMolecular OncologyCancer TranscriptomicsNoncoding Rna BiologyNoncoding Rna FunctionNoncoding Rna In CancerNoncoding Rna TranscriptomicsTranscriptomic ProfilingAcute Myeloid Leukemia BiologyAcute Myeloid Leukemia TherapyLong Non-coding Ribonucleic AcidsLong Non-coding Rna BiomarkersLong Noncoding Rna Expression AnalysisLong Noncoding Rna ProfilingNoncoding Rna Expression ProfilingPredictive Risk Stratification
OBJECTIVE: Our study aimed to investigate the correlation of long noncoding RNA maternally expressed gene 3 expression with clinical features, treatment response, and survival profiles in patients with acute myeloid leukemia. METHODS: patients with acute myeloid leukemia (prior to treatment) and 30 healthy donors (after enrollment) were collected, and long noncoding RNA maternally expressed gene 3 expression was detected by reverse transcription quantitative polymerase chain reaction. According to median value of long noncoding RNA maternally expressed gene 3 expression in patients with acute myeloid leukemia, they were divided into long noncoding RNA maternally expressed gene 3 high expression and low expression patients (which were further categorized as low---, low--, and low- expression patients). RESULTS: Long noncoding RNA maternally expressed gene 3 expression was decreased in patients with acute myeloid leukemia compared to healthy donors. Besides, receiver operating characteristic curve displayed that long noncoding RNA maternally expressed gene 3 distinguished patients with acute myeloid leukemia from healthy donors. In patients with acute myeloid leukemia, long noncoding RNA maternally expressed gene 3 low expression was associated with poor-risk stratification but was not correlated with age, gender, French-American-Britain classification, or white blood cell level. For prognosis, complete remission rate was lowest in long noncoding RNA maternally expressed gene 3 low--- expression patients, followed by long noncoding RNA maternally expressed gene 3 low-- expression patients, long noncoding RNA maternally expressed gene 3 low- expression patients, and was highest in long noncoding RNA maternally expressed gene 3 high expression patients; Kaplan-Meier curves displayed that lower long noncoding RNA maternally expressed gene 3 expression was associated with reduced event-free survival and overall survival; Cox regression analysis showed that lower long noncoding RNA maternally expressed gene 3 expression independently predicted decreased event-free survival and worse overall survival in patients with acute myeloid leukemia. CONCLUSION: Long noncoding RNA maternally expressed gene 3 may function as a novel marker for effective surveillance and management of acute myeloid leukemia.
17
Cytarabine Dose for Acute Myeloid Leukemia
Bob Löwenberg, Thomas Pabst, Edo Vellenga et al. · New England Journal of Medicine · 2011 · 407 citations · Full text
Juanjuan Zhu, Shanshan Liu, Fuqiang Ye et al. · PLoS ONE · 2015 · 172 citations · Full text
Yuanyuan Lyu, Jiacheng Lou, Yi Yang et al. · Leukemia · 2017 · 127 citations · Full text
Life Sciences, Genetics, Oncology +17